Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There are limited real world data on ixazomib, lenalidomide, and dexamethasone (IRd) in multiply relapsed myeloma. We analyzed outcomes of 116 patients who received IRd predominantly at second and subsequent relapse including those refractory to proteasome inhibitors (PIs). With a median follow up 16.3 months, the overall response rate was 66.9%; median progression-free survival (PFS) was 17.7 months with median overall survival (OS) not reached (NR). PFS and OS were significantly shorter in advanced disease (PFS; 12.6 vs. 21.2 months (p = .01), OS; 15.9 months vs. NR (p = .01) for ISS3 vs. ISS 1&2, respectively). PFS and OS were significantly shorter in clinical high risk (CHR) compared to standard risk (SR) patients (PFS; 9.3 months vs. NR (p = .001), OS; 11.5 months vs. NR (p 

Original publication

DOI

10.1080/10428194.2020.1864355

Type

Journal article

Journal

Leuk Lymphoma

Publication Date

06/2021

Volume

62

Pages

1396 - 1404

Keywords

Refractory, effectiveness, ixazomib, lenalidomide, real world, safety, Antineoplastic Combined Chemotherapy Protocols, Boron Compounds, Dexamethasone, Glycine, Humans, Lenalidomide, Multiple Myeloma, Neoplasm Recurrence, Local, United Kingdom